Development of therapeutic antibodies for the treatment of diseases

Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years.

A long history: An introduction to biosimilars and monoclonal antibodies (mAbs)

... but who is responsible for creating monoclonal antibodies? This discovery is down to the work of César Milstein and Georges Köhler, who won the Nobel Prize in Physiology or Medicine in 1984 for their production method. By fusing lymphocytes (lymphatic cells) with myeloma (tumour) cells, they were able to create an immortal cell line capable of producing specific antibodies...

Future perspectives of therapeutic monoclonal antibodies

Attention to therapeutic monoclonal antibodies has been dramatically increasing year by year. Their highly specific targeting of antigens can provide very effective medical treatment, and the advent of molecular-targeting medicine is allowing development of a new generation of therapeutic agents.

History of Monoclonal Antibodies

César Milstein began researching somatic mutation in the 1960s, which he hypothesised was responsible for antibody diversity and specificity. He investigated this mechanism in antibodies produced by myeloma cells, which were readily available at the time. However, the exact antigen specificity of these cells was unknown, making it difficult to study their molecular mechanisms.

History of the Monoclonal Antibody - Part I

Monoclonal antibodies are a pretty ubiquitous research tool. In fact, you’d be hard-pressed to find a lab without a freezer full of them. They have myriad uses from examining protein localization within a tissue (e.g., IHC), to isolating a particular protein out of a proteinaceous soup (e.g. WB, IP), or separating a specific cell population from the tissue milieu (e.g., FACS). They are such a fundamental part of so many research strategies that without them there wouldn’t be many tricks left up our collective sleeve. So, it’s a little strange to think that we really haven’t had them at our disposal for all that long .

Monoclonal antibodies for infectious diseases

Science will only fulfill its promises when the benefits are equally shared by the really poor of the world —César Milstein, Un Fueguito

Monoclonal Antibodies: A Tool in Clinical Research

Monoclonal antibodies (MAbs) are an old immunological tool with applications in the fields of immunology, biotechnology, biochemistry, and applied biology. Production of monoclonal antibodies using hybridoma technology was discovered in 1975 by Georges Kohler of West Germany and Cesar Milstein of Argentina.

Monoclonal Antibodies: How to Navigate the Naming Scheme

Monoclonal antibodies (mAbs) are a relatively new, unique class of biologic agents. In the short time they have been commercially available, treatments have been developed for autoimmune and alloimmune diseases, antitumor therapy, antiplatelet therapy, and numerous other indications. Despite the rapid growth in this field, mAbs are poorly understood by a large number of providers and pharmacists.

Monoclonal antibody discovery: current status and future perspectives

Since the first description of how to generate monoclonal antibodies was published in the 1970s, this field of research has grown tremendously.

Monoclonal antibody drugs – a history of success and a bright future!

The use of monoclonal antibody drugs for therapeutic outcomes remains a topic of high interest throughout the research community.

The Future of Monoclonal Antibodies

Over the last decade monoclonal antibodies (mAbs) have been one of the fastest-growing classes of pharmaceutical drugs. As more potential targets are identified through a greater understanding of molecular mechanisms underlying disease, it offers opportunities for the development of new mAb-based drugs.

What Monoclonal Antibodies Are — and Why We Need Them As Well As a Vaccine

Monoclonal antibodies are human-made proteins that mimic natural antibodies in the immune system.